News >

Tripathy Highlights Neoadjuvant Advances in HER2+ Breast Cancer

Danielle Bucco
Published: Wednesday, May 03, 2017

Debu Tripathy, MD

Debu Tripathy, MD

The treatment paradigm for the neoadjuvant setting of HER2-positive breast cancer continues to evolve, offering new opportunities to improve patient outcomes, according to Debu Tripathy, MD.

(MBCC), Tripathy, a professor and chairman in the Department of Breast Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed current and emerging treatment strategies in the neoadjuvant setting for patients with HER2-postive breast cancer.

OncLive: Please provide an update on neoadjuvant treatment strategies in HER2-positive breast cancer.

Tripathy: The use of neoadjuvant therapy for HER2-positive breast cancer is an area of increasing understanding, knowledge, and interest. We know that patients clearly achieve a higher chance of a pCR with the addition of trastuzumab to standard chemotherapy. This occurs in both the neoadjuvant and adjuvant settings, which had led to it being the standard of care. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication